Vascular Endothelial Growth Factor and its Soluble Receptor-1 as Surrogate Markers for Subjects with High-risk of Cardiovascular Disease

2014 ◽  
Vol 5 (2) ◽  
pp. 35-42
Author(s):  
Vipa Boonkitticharoen ◽  
Chanika Sritara ◽  
Prin Vathesatogkit ◽  
Supakajee Saengruang-Orn ◽  
Wipa Ratanachaiwong ◽  
...  
Keyword(s):  
Cardiovascular Disease ◽  
Vascular Endothelial Growth Factor ◽  
Growth Factor ◽  
High Risk ◽  
Surrogate Markers ◽  
Vascular Endothelial ◽  
Soluble Receptor ◽  
Endothelial Growth Factor

scholarly journals Keeping blood vessels out of sight

eLife ◽  
2013 ◽  
Vol 2 ◽  
Author(s):  
Dawn Sim ◽  
Marcus Fruttiger
Keyword(s):  
Vascular Endothelial Growth Factor ◽  
Growth Factor ◽  
Blood Vessels ◽  
Vascular Endothelial ◽  
Soluble Receptor ◽  
Outer Retina ◽  
Endothelial Growth Factor

Researchers have identified a soluble receptor that prevents blood vessels forming in the outer retina—a process that can lead to blindness—by sequestering vascular endothelial growth factor.

scholarly journals Anti-inflammatory and immunomodulatory effects of rosuvastatin in patients with low-to-moderate cardiovascular risk

2021 ◽  
Vol 72 (2) ◽  
pp. 303-315
Author(s):  
ANA VAVLUKIS ◽  
MARIJA VAVLUKIS ◽  
ALEKSANDAR DIMOVSKI ◽  
GORDANA PETRUSHEVSKA ◽  
ALEKSANDAR EFTIMOV ◽  
...  
Keyword(s):  
Cardiovascular Disease ◽  
Vascular Endothelial Growth Factor ◽  
Cardiovascular Risk ◽  
Growth Factor ◽  
Epidermal Growth Factor ◽  
Vascular Endothelial ◽  
Routine Monitoring ◽  
Epidermal Growth ◽  
Anti Inflammatory ◽  
Endothelial Growth Factor

Abstract Statins have shown anti-inflammatory pleiotropic effects in subjects with/at risk of cardiovascular disease. The aim of this study was to evaluate the inflammatory/immunomodulatory properties of rosuvastatin in subjects at low-to-moderate cardiovascular risk. Data was collected from patients’ records, physical examination and blood sampling. Subjects were assigned to rosuvastatin 20 mg per day. Rosuvastatin significantly decreased C-reactive protein (p = 0.045), and increased vascular endothelial growth factor (p = 0.004) and epidermal growth factor (p = 0.009). A multivariate analysis identified total cholesterol (p = 0.027) and vascular endothelial growth factor (p = 0.011) to be independently associated with rosuvastatin treatment. Given beneficial/harmful role of growth factors, vascular endothelial growth factor (VEGF) and epidermal growth factor (EGF), in cardiovascular disease, one would suggest the need for routine monitoring of growth factor levels, especially in patients on long-term statin therapy.

Sign in / Sign up

Export Citation Format

Share Document